# About BPC-157 TB-500 — an editorial digest of the Wolverine literature

> About the BPC-157 TB-500 research console: an independent editorial project that publishes cited summaries of the peer-reviewed literature on the Wolverine blend's two constituents. Not a clinic, not a vendor.

What this project is, what the "doctor" in the name does and does not mean, and how the record is read.

## What Wolverine Doctor is

Wolverine Doctor is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157 TB-500 — the two-peptide "Wolverine" blend. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and the public regulatory record.

The site is built as a research console: each finding is read against the constituent it belongs to — BPC-157 on one channel, TB-500 on the other — and the blend-level gaps are marked rather than smoothed over. Where the published record has no answer, the console says so.

## What the "Doctor" in the name means

The "doctor" modifier in the domain name is editorial framing — a position this publisher occupies relative to the literature, not a claim about services. It signals the register we read in: careful with mechanism, exact with doses-as-studied, and as rigorous with the FDA 503A and WADA record as with the science.

It is not a clinic, a physician, or a consultation service. There is no medical team behind this page, no prescriber, and no treatment offered. When we discuss the lawful compounded-access pathway on the [Wolverine legal status and FDA 503A compounding access](/legal-status) page, we describe the general regulatory landscape — never a route to obtain anything, and never advice.

## How we handle the evidence

Two rules govern the content. First, every quantitative claim maps to a citation in the reference list — doses, half-lives, effect descriptions, and regulatory facts all carry a source. Second, the constituent-versus-blend distinction is never blurred: single-compound animal findings are labeled as such, and the absence of any controlled combination trial is stated plainly wherever the synergy question arises.

We also preserve the identity caveat that runs through the TB-500 literature — that most efficacy data attributed to it were generated with full-length Thymosin Beta-4, not the marketed heptapeptide [4]. The point of the console is to let a reader see exactly where each evidence point sits, and exactly where the record runs out.

---

Two constituent channels read off one console — BPC-157 traced to its studies and TB-500 to its own, the repair-signal node where they converge left dark because no combination trial exists, and the FDA 503A and WADA marks posted before anything else; no clinic behind the readout and nothing here dispensed.